Cardio-Oncology Midwest Regional Symposium
心脏肿瘤学中西部地区研讨会
基本信息
- 批准号:10391683
- 负责人:
- 金额:$ 1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-15 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:AgingArrhythmiaAttentionAutonomic DysfunctionAwarenessCancer Death RatesCancer PatientCancer SurvivorCardiacCardiomyopathiesCardiotoxicityCardiovascular DiseasesCardiovascular systemCaregiversCause of DeathChemotherapy and/or radiationClinicalDiseaseEarly DiagnosisEducational ActivitiesEventFunctional disorderFutureGeneral PractitionersGrowthHealthHeart Valve DiseasesHeart failureHospitalistsHypertensionImmune TargetingImmunotherapyIschemiaKnowledgeMalignant NeoplasmsMidwestern United StatesMissionMonitorMorbidity - disease rateMyocardial InfarctionMyocardial dysfunctionNational Heart, Lung, and Blood InstituteOncologistOncologyOutcomePatient CarePatientsPericardial body locationPeripheralPharmacistsPopulationPreventionProviderRadiationRadiation therapyResearchRiskRisk FactorsSpecialistSurvivorsTherapeuticTherapeutic AgentsToxic effectTreatment-Related CancerUnited States National Institutes of HealthUpdateVariantVentricular Arrhythmiaadverse outcomeagedarmcancer carecancer riskcancer therapycardiovascular healthcare providerseffective therapyimprovedknowledge basemortalitynew therapeutic targetpreventprogramsroutine careside effectsymposiumtooltreatment strategy
项目摘要
Paradigms in Cardiovascular Care of the Cancer Patient/Survivor – Biennial Cardio-
Oncology Midwest Regional Educational Symposium
Abstract
Second to cardiovascular disease (CVD) in the U.S., cancer remains the leading cause of death
in the world. Nonetheless, the overall death rate from cancer has declined, and the number of
cancer survivors has increased as a result of advancements in oncologic treatment, and greater
attention by providers to prevention and surveillance for adverse outcomes. By January 1, 2030,
it is estimated that the population of cancer survivors will increase to more than 22.1 million due
to the growth and aging of the population alone.
CVD is the major cause of morbidity and mortality among cancer survivors, and is considered to
be a major cause of mortality among cancer survivors aged 15 to 39 years old. Many
therapeutic approaches to cancer significantly increase the risk of cardiomyopathy, ischemia,
cardiovascular events (including myocardial infarction and ventricular arrhythmias), and
hypertension.
Cardio-oncology is a nascent field that focuses on preventing adverse cardiovascular outcomes
in patients with active cancer and improving the overall cardiovascular health of cancer
survivors. This involves specific understanding of interactions between cancer and the
cardiovascular system; as well as intrinsic knowledge of cancer therapeutic agents including
chemotherapy, radiation therapy, and newer targeted therapies/immunotherapy. The field of
cardio-oncology is becoming more specialized with constant variations in cancer treatment; and
emphasizes a great need to educate and keep clinician up to date. This is particularly important
for primary doctors and other caregivers that remain peripherally involved in routine care of
cancer patient; and need to be cognizant or aware of cancer therapy(ies) received, short and
long-term side effects, and management strategies.
We propose an educational activity that will provide the latest clinical updates in the treatment of
cardiovascular conditions in an oncology setting. The purpose of this program is to familiarize
primary care providers, hospitalists, oncologists, cardiologists, advanced practice providers,
pharmacists, and trainees, with updated treatment of cardiac conditions seen in cancer patients/
survivors; as well as identify ongoing research to further improve our understanding of cancer
therapy-related cardiovascular dysfunction to further enhance management strategies for the
future. Given the paucity of cardio-oncology specialists in many parts of the U.S., the program
will arm general practitioners with practical tools to promote the prevention and treatment of
CVD as a result of cancer therapy, to help their cancer patients live longer and healthier lives.
癌症患者/幸存者心血管护理的范例-两年一次的心脏病学会议
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tochukwu E.M Okwuosa其他文献
Tochukwu E.M Okwuosa的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
DEVELOPING A HUMAN STEM CELL-DERIVED HEART MODEL TO CHARACTERIZE A NOVEL ARRHYTHMIA SYNDROME
开发人类干细胞衍生的心脏模型来表征新型心律失常综合征
- 批准号:
495592 - 财政年份:2023
- 资助金额:
$ 1万 - 项目类别:
Preliminary Study to Establish Heavy Ion Ablation Therapy for Lethal Ventricular Arrhythmia
重离子消融治疗致死性室性心律失常的初步研究
- 批准号:
23K14885 - 财政年份:2023
- 资助金额:
$ 1万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Arrhythmia Mechanisms Modulated by Intercalated Disc Extracellular Nanodomains
闰盘细胞外纳米结构域调节心律失常的机制
- 批准号:
10668025 - 财政年份:2023
- 资助金额:
$ 1万 - 项目类别:
Development of a next-generation telemonitoring system for prognostic prediction of the onset of heart failure and arrhythmia
开发下一代远程监测系统,用于心力衰竭和心律失常发作的预后预测
- 批准号:
23K09597 - 财政年份:2023
- 资助金额:
$ 1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The role of inflammation in the pathogenesis of atrial fibrillation: Implications for atrial remodeling pathophysiology and for early atrial arrhythmia recurrences following radiofrequency ablation and pulsed field ablation
炎症在心房颤动发病机制中的作用:对心房重塑病理生理学以及射频消融和脉冲场消融后早期房性心律失常复发的影响
- 批准号:
514892030 - 财政年份:2023
- 资助金额:
$ 1万 - 项目类别:
WBP Fellowship
Improved arrhythmia ablation via MR-guided robotic catheterization and multimodal clinician feedback
通过 MR 引导的机器人导管插入术和多模式临床医生反馈改善心律失常消融
- 批准号:
10638497 - 财政年份:2023
- 资助金额:
$ 1万 - 项目类别:
Prototype development and validation of soft robotic sensor arrays for mapping cardiac arrhythmia
用于绘制心律失常的软机器人传感器阵列的原型开发和验证
- 批准号:
10722857 - 财政年份:2023
- 资助金额:
$ 1万 - 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
- 批准号:
10733915 - 财政年份:2023
- 资助金额:
$ 1万 - 项目类别:
A novel regulator of Ca2+ homeostasis and arrhythmia susceptibility
Ca2 稳态和心律失常易感性的新型调节剂
- 批准号:
10724935 - 财政年份:2023
- 资助金额:
$ 1万 - 项目类别:
Novel Stellate Ganglia Chemo-ablation Approach to Treat Cardiac Arrhythmia and Cardiac Remodeling in Heart Failure
新型星状神经节化疗消融方法治疗心律失常和心力衰竭心脏重塑
- 批准号:
10727929 - 财政年份:2023
- 资助金额:
$ 1万 - 项目类别: